Investing.com - Adaptimmune Therapeutics reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $0.5M. Analysts polled by Investing.com anticipated EPS of $-0.24 on revenue of $7.94M.
Adaptimmune Therapeutics shares are up 626.67% from the beginning of the year and are trading at $8.72 , down-from-52-week-high.They are outperforming the Nasdaq which is up 22.58% from the start of the year.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by J&J on Thursday, July 16, 2020, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on Thursday, July 23, 2020 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.43B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar